Skip to content

Clinical observation on the efficacy of atomization of Zhichuanling injection in the treatment of asthmatic bronchitis

Observation on the clinical efficacy of Zhichuanling injection atomization in the treatment of mild and moderate bronchial asthma at acute attack stage (hot asthma)

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300069215
Enrollment
Unknown
Registered
2023-03-09
Start date
2023-04-06
Completion date
Unknown
Last updated
2025-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthmatic bronchitis

Interventions

Experimental group:Antiasthmatic injection, atomized inhalation with 2ml of normal saline, 1 piece/time, 2 times/day
Control group:Budesonide suspension for inhalation, add 2ml of normal saline for atomization inhalation (use according to the instructions)

Sponsors

Taizhou Jiangyan Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 6 Years

Inclusion criteria

Inclusion criteria: 1. Aged 1-6 years, no gender limit. 2. Patients who meet the diagnostic criteria for asthmatic bronchitis in the Diagnosis and Treatment of Common Diseases of Pediatrics with Traditional Chinese and Western Medicine or the syndrome differentiation criteria for asthmatic disease of traditional Chinese medicine (syndrome is phlegm-heat closing lung and related syndromes). 3. The family members of the children signed the informed consent voluntarily.

Exclusion criteria

Exclusion criteria: 1. Patients with severe genetic diseases; 2. Patients with cardiac, liver and renal dysfunction; 3. Patients with severe pneumonia, congenital malformation of respiratory system, bronchial asthma, severe pneumonia or history of lung surgery; 4. Patients with severe infection and endocrine system diseases; 5. Patients with malignant tumor; 6. Glaucoma patients; 7. Known allergy to test drug components and allergic constitution; 8. Patients who have participated or are participating in other clinical trials within 1 month; 9. Patients considered inappropriate to participate in this clinical trial.

Design outcomes

Primary

MeasureTime frame
Efficacy of clinical symptoms (control rate);

Secondary

MeasureTime frame
Effective time and recovery time of cough, wheezing, wheezing/rale;Efficacy of cough, wheezing, wheezing/rale single symptom;Time of onset and disappearance of clinical symptoms;

Countries

China

Contacts

Public ContactLyu Hongfen

Taizhou Jiangyan Traditional Chinese Medicine Hospital

1129038134@qq.com+86 523 8823 4500

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026